Editas Medicine vs 4D Molecular Therapeutics
EDIT and FDMT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EDIT and FDMT compare
4D Molecular Therapeutics is the larger company, worth 2.6 times as much as Editas Medicine ($938M against $366M).
4D Molecular Therapeutics grew revenue faster over the last twelve months (278712% versus 7.4% for Editas Medicine).
Editas Medicine keeps more of each dollar of sales as profit, with a net margin of −145% compared with −195% at 4D Molecular Therapeutics.
4D Molecular Therapeutics scores higher on the StockData Score (7 against 3 for Editas Medicine), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EDIT | FDMT |
|---|---|---|
| Size and price | ||
| Market cap | $366M | $938M |
| Share price | $2.38 | $12.99 |
| Change, 1 year | −5.6% | 27.7% |
| Change, 5 years | −93.3% | −43.7% |
| Beta (5Y) | 2.19 | 1.35 |
| Employees | 87 | 196 |
| StockData Score | ||
| Total score | 3 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.3× (better) | 10.2× |
| P/B | 4.3× | 2.3× (better) |
| FCF yield | −30.2% | – |
| Fair value | $1.62 | $12.76 |
| Margin of safety | −47.2% | −1.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 7.4% | 278712% (better) |
| Revenue growth, 5Y average | −14.9% | 44.3% (better) |
| Profitability | ||
| Operating margin | −152% (better) | −214% |
| Net margin | −145% (better) | −195% |
| FCF margin | −222% | – |
| Return on equity | −147% | −43.3% (better) |
| Return on invested capital | – | −161% |
| Financial health | ||
| Debt / equity | 0.67 | 0.05 (better) |
| Interest coverage | −10.6× | – |
| Current ratio | 2.82 | 8.03 (better) |
| Altman Z-score | −9.39 | 3.87 (better) |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −36.6% | – |
| Shareholder yield | −36.6% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 78.3% | 80.5% |
| Held by insiders | 0.45% | 2.1% |
| Insider net buying, 12 months | −$107K (better) | −$5.3M |
| Short interest, % of float | 25.3% | 15.4% |
Go deeper
- EDIT stock overview
- EDIT income statement
- EDIT valuation and score
- FDMT stock overview
- FDMT income statement
- FDMT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.